Literature DB >> 9588210

Characterization of the mouse Myoc/Tigr gene.

S I Tomarev1, E R Tamm, B Chang.   

Abstract

Mutations in the myocilin (MYOC), also known as Trabecular meshwork-Inducible Glucocorticoid Response (TIGR) gene can lead to juvenile open-angle glaucoma in human and may be responsible for at least 3% of primary open-angle glaucoma. To develop a mouse model of primary open angle glaucoma, and to get deeper insight into the mechanisms of the MYOC/TIGR gene regulation and function, we have isolated and characterized full size mouse Myoc/Tigr cDNA and genomic clones. The mouse and human MYOC/TIGR genes have the same exon-intron structure and contain 3 exons, although the mouse gene is 6 kb shorter than the human gene (10 kb versus 16 kb) due to differences in the length of introns. The MYOC/TIGR gene encodes a moderately conserved protein, which is 82% identical between human and mouse. The encoded protein is 14 amino acids shorter at the N-terminus in the mouse than in the human (490 versus 504 amino acids). Mouse and human MYOC/TIGR genes show a similar pattern of expression in adult ocular and nonocular tissues. The mouse Myoc/Tigr gene was mapped to Chromosome 1 at position 82.8 cM from the centromere. All residues, which were identified in the human MYOC/TIGR protein as critical for glaucoma development, are conserved in the mouse Myoc/Tigr.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9588210     DOI: 10.1006/bbrc.1998.8541

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  17 in total

Review 1.  Glaucoma-associated myocilin: a better understanding but much more to learn.

Authors:  Zachary T Resch; Michael P Fautsch
Journal:  Exp Eye Res       Date:  2008-08-29       Impact factor: 3.467

2.  Myocilin regulates cell proliferation and survival.

Authors:  Myung Kuk Joe; Heung Sun Kwon; Radu Cojocaru; Stanislav I Tomarev
Journal:  J Biol Chem       Date:  2014-02-22       Impact factor: 5.157

3.  Myocilin interacts with syntrophins and is member of dystrophin-associated protein complex.

Authors:  Myung Kuk Joe; Changwon Kee; Stanislav I Tomarev
Journal:  J Biol Chem       Date:  2012-02-25       Impact factor: 5.157

4.  Efficient in vivo doxycycline and cre recombinase-mediated inducible transgene activation in the murine trabecular meshwork.

Authors:  Pu Liu; Xueyao Fu; Randy L Johnson
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-02-23       Impact factor: 4.799

5.  Myocilin, a glaucoma-associated protein, promotes cell migration through activation of integrin-focal adhesion kinase-serine/threonine kinase signaling pathway.

Authors:  Heung Sun Kwon; Stanislav I Tomarev
Journal:  J Cell Physiol       Date:  2011-12       Impact factor: 6.384

6.  Myocilin stimulates osteogenic differentiation of mesenchymal stem cells through mitogen-activated protein kinase signaling.

Authors:  Heung Sun Kwon; Thomas V Johnson; Stanislav I Tomarev
Journal:  J Biol Chem       Date:  2013-04-29       Impact factor: 5.157

7.  Targeted Disruption of the Myocilin Gene (Myoc) Suggests that Human Glaucoma-Causing Mutations Are Gain of Function.

Authors:  B S Kim; O V Savinova; M V Reedy; J Martin; Y Lun; L Gan; R S Smith; S I Tomarev; S W John; R L Johnson
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

8.  Genetically increasing Myoc expression supports a necessary pathologic role of abnormal proteins in glaucoma.

Authors:  Douglas B Gould; Laura Miceli-Libby; Olga V Savinova; Mario Torrado; Stanislav I Tomarev; Richard S Smith; Simon W M John
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

9.  Myocilin mediates myelination in the peripheral nervous system through ErbB2/3 signaling.

Authors:  Heung Sun Kwon; Thomas V Johnson; Myung Kuk Joe; Mones Abu-Asab; Jun Zhang; Chi Chao Chan; Stanislav I Tomarev
Journal:  J Biol Chem       Date:  2013-07-29       Impact factor: 5.157

10.  Transgenic mice expressing the Tyr437His mutant of human myocilin protein develop glaucoma.

Authors:  Yu Zhou; Oleg Grinchuk; Stanislav I Tomarev
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-05       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.